Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955752 | 0.82 | KMT2A (0.47) | ALDH1A1HSD17B10GPR35KMT2AMEN1 | |
| SCHEMBL3644484 | 0.78 | ALDH1A1 (0.67) | ALDH1A1HSD17B10GPR35KMT2AMEN1 | |
| SCHEMBL635165 | 0.77 | ALDH1A1 (1.00) | ALDH1A1HSD17B10GPR35KMT2AMEN1 | |
| SCHEMBL2824579 | 0.76 | ALDH1A1 (0.50) | ALDH1A1HSD17B10GPR35KMT2AMEN1 | |
| SCHEMBL20377757 | 0.75 | ALDH1A1 (0.52) | ALDH1A1HSD17B10GPR35KMT2AMEN1 | |
| SCHEMBL1301289 | 0.75 | GPR35 (0.61) | ALDH1A1HSD17B10GPR35KMT2AMEN1 | |
| SCHEMBL10645207 | 0.75 | ALDH1A1 (0.52) | ALDH1A1HSD17B10GPR35KMT2AMEN1 | |
| SCHEMBL9427988 | 0.75 | ALDH1A1 (0.70) | ALDH1A1HSD17B10GPR35KMT2AMEN1 | |
| SCHEMBL1517106 | 0.75 | ALDH1A1 (0.70) | ALDH1A1HSD17B10GPR35KMT2AMEN1 | |
| SCHEMBL21068952 | 0.74 | CYP19A1 (0.44) | ALDH1A1HSD17B10GPR35KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109535397-B | Stable organic light-emitting free radical polymer and OLED (organic light-emitting diode) device based on same | 吉林大学 | 2021-04-27 | — | — | CN | disclosed |
| EP-2964633-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-04-19 | — | — | EP | disclosed |
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2017-03-23 | — | — | US | disclosed |
| US-9540345-B2 | Antiviral compounds | HOFFMANN-LA ROCHE INC. (US) | 2017-01-10 | — | — | US | disclosed |
| EP-2964633-A1 | ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20150368228-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2015-12-24 | — | — | US | disclosed |
| WO-2014135471-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| US-5969155-A | Conversion of trinitrotoluene into high value compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1999-10-19 | — | — | US | disclosed |
| US-4968847-A | INTERMEDIATES FOR INSECTICIDES | ISTITUTO GUIDO DONEGANI S.P.A. (IT) | 1990-11-06 | — | — | US | disclosed |
| US-4929772-A | CHLORO, FLUORO CARBINOL, INTERMEDIATES FOR INSECTICIDES | ISTITUTO GUIDO DONEGANI (IT) | 1990-05-29 | — | — | US | disclosed |
| US-4602041-A | TREATMENT OF DIARRHEA | BEECHAM GROUP P.L.C. (GB) | 1986-07-22 | — | — | US | disclosed |
| EP-0187674-A2 | Process for the preparation of polyhalogenated carbinols | ISTITUTO GUIDO DONEGANI S.p.A. (IT) | 1986-07-16 | — | — | EP | disclosed |
| EP-0087218-B1 | GUANIDINE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1985-05-02 | — | — | EP | disclosed |
| EP-0087218-A1 | Guanidine derivatives | BEECHAM GROUP PLC (GB) | 1983-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | ALDH1A1 190/4885HSD17B10 1495/4885GPR35 4007/4885 |
| US-20150368228-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | ALDH1A1 190/4885HSD17B10 1495/4885GPR35 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.